China Tracker - Details for China Biologic Products (CBPO)


Warning: fopen(http://finance.yahoo.com/d/quotes.csv?s=CBPO&f=snl1a2xf6): failed to open stream: HTTP request failed! HTTP/1.0 403 Forbidden in /home/fixyou/public_html/tracker_details.php on line 58

Warning: fgetcsv() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 60

Warning: fclose() expects parameter 1 to be resource, boolean given in /home/fixyou/public_html/tracker_details.php on line 61
 China Biologic Products
Shares Outstanding (MRQ): 25.68 mill
New Shares / Dilution (TTM): -0.79 mill-2.99%
New Shares / Dilution (since Dec 31, 2008): 4.12 mill19.13% 
Cash (MRQ): 56.31 mill0.00%
Account Receivables (MRQ): 13.31 mill0.00%
Account Receivables (Q/Q): + 3.18 mill  
Long-Term Debt (MRQ): 4.42 mill0.00%
Revenue Growth (Q/Q): -3.40% 
Revenue Growth (Y/Y): 27.21% 
Net Income Growth (Q/Q): 5.99% 
Net Income Growth (Y/Y): 5.16% 
EPS Growth (Y/Y): 8.40% 
Net Margin (Q/Q): 23.1% (21.1%)2.00% 
Net Margin (Y/Y): 23.1% (28.0%)-4.80% 
EPS | P/E (2 MRQ Projection): $1.210.00 
CFPS | P/CF (2 MRQ Projection): $0.810.00 
Price/Sales (2 MRQ Projection): 0.00
Price/Book (MRQ): 0.00 
Auditor: KPMG
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2011-04-01): $1.700.00 
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2006-07-19 
Uplisting to Senior Exchange: on 2009-12-02 at $8.45 (-100.00% since Uplisting)

 Business Outlook

China Biologic Products today announced that the Guizhou Provincial Health Department has issued the revised "Plan for Guizhou Provincial Blood Collection Institutional Setting (2011-2014)". The Revised Plan reduces the number of counties that are permitted to set up plasma collection stations from the originally proposed 10 counties to 4 counties. China Biologic's 54% indirectly owned subsidiary, Guizhou Taibang Biological Technologies Co., Ltd., currently has 6 active plasma collection stations in the Guizhou Province. Among the 6 active plasma collection stations, 2 are located in the counties included in the Revised Plan (Pu Ding and Huang Ping) and are currently expected not to be affected directly by the Revised Plan.

Based on the Company's preliminary understanding of the Revised Plan, subject to further clarifications from Guizhou Provincial government regarding the implementation of the Revised Plan, the Company currently anticipates the licenses of its 4 other plasma collection stations in Dan Zhai, Wei Ning, San Sui, and Na Yong counties may not be renewed (until at least 2014) after their respective plasma collection permits expire at the end of July 2011. The Company's 4 stations in Dan Zhai, Wei Ning, San Sui, and Na Yong counties together accounted for approximately 34.1% of China Biologic's total plasma collection by volume in 2010. In addition, 1 inactive plasma collection station that the Company purchased from the government is unlikely to be licensed as planned, because it is in Zhengyuan County, a location not included in the Revised Plan.

The 2 active plasma stations in the counties included in the Revised Plan that are expected to continue operating are scheduled for relicensing before the end of July. The relicensing will require inspection of the plasma collection stations by provincial and other government officials. While the Company believes it meets or exceeds all inspection requirements at those stations, it is not yet clear what influence on the inspections the Revised Plan may have, if any.

(Source: PR Newswire, 2011-07-15)

China Biologic Products today announced that the Company has received oral notification from the Guizhou Provincial Health Department that the Guizhou Provincial Government has suspended the implementation of its recently issued "Plan for Guizhou Provincial Blood Collection Institutional Setting (2011-2014)". The Company also was asked to return its copy of the Plan to the Guizhou Provincial Health Department. It is currently not clear what further action the Guizhou Provincial Government may take, including, among other things, revising the Plan, implementing the Plan, or revoking the Plan, and whether the Plan, if implemented, would cause no closures, fewer closures, or more closures of plasma collection stations located in Guizhou Province.

(Source: PR Newswire, 2011-07-13)

China Biologic Products today announced that the Guizhou Provincial Health Department has issued a "Plan for Guizhou Provincial Blood Collection Institutional Setting (2011-2014)". Based on the Company's preliminary understanding of the Plan, subject to further clarifications from Guizhou Provincial government regarding the implementation of the Plan, the Company currently anticipates the licenses of its 3 other plasma collection stations in Dan Zhai, Wei Ning, and San Sui counties may not be renewed (until at least 2014) after their respective plasma collection permits expire at the end of July 2011. The Company's 3 stations in Dan Zhai, Wei Ning, and San Sui counties together accounted for about 24.5% of the Company's total plasma collection by volume in 2010. In addition, 1 inactive plasma collection station that the Company purchased from the government is unlikely to be licensed as planned, because it is in Zhengyuan County, a location not included in the Plan.

The 3 active plasma stations in the counties included in the Plan that are expected to continue operating are scheduled for relicensing before the end of July. The relicensing will require inspection of the plasma stations by provincial and other government officials. While the Company believes it meets or exceeds all inspection requirements at those stations, it is not yet clear what influence on the inspections the new Plan may have, if any.

The Company is currently evaluating the effect of the Plan and the anticipated closing of the 3 active plasma collection stations including, among other items, the potential reduction in China Biologic's previously issued financial guidance for the year 2011, potential reduction in its business operations and financial performance in current and future periods, potential assets impairments associated with these plasma collection stations and the 1 inactive station, and other possible effects.

(Source: PR Newswire, 2011-07-11)

    see all Business Outlook notes

 Analyst Coverage (show more)
2011-07-12Rodman & RenshawDowngradeUnder Reviewn/a
2010-12-06Brean MurrayReiterationBuy$20.00
2010-12-06Rodman & RenshawReiterationOutperform$17.00
2010-11-16Rodman & RenshawReiterationOutperform$17.00
2010-08-16Rodman & RenshawReiterationOutperform$17.00

CBPO is currently followed by 2 analysts. 1 give the stock a positive rating, 0 rate it neutral and 1 give it a negative rating.


    see all Analyst Ratings

 Investor Presentations
2011-06-07 (HTML)   VIEW
2011-03-07 (HTML)   VIEW
2010-05-08 (HTML)   VIEW
2010-03-09 (HTML)   VIEW
CBPO
Healthcare & Drugs
SCORE
4
READ: Score Cards Explained
SAFETY/RISK SCORE
MODERATE RISK
DETAILS: Safety/Risk Model for CBPO
Current Price:  n/a
F10k Day (2008-02-06): -100.00%$4.01
2009 Close: -100.00%$12.08
2010 Close: -100.00%$16.39
2011 Close: -100.00%$10.46
High (2012-07-20): -100.00%$11.00
Low (2012-05-25): -100.00%$7.07
Exchange:
Market Capitalization: n/a
Total Shares: 25.68 mill
Float: n/a
Avg Volume: 22.50 k
Short Interest: 1.10 mill
Short Ratio: 17.49%49.0 d
Last Quarter: 2011-03-31
Revenue (MRQ): 34.47 mill
Net Income (MRQ): 7.97 mill
Op. Cash Flow (MRQ): 2.88 mill
all financial data provided without warranty